Clinical trial · Interventional
Phase II Study of TAS-106 to Treat Head and Neck Cancer
Phase II Study of TAS-106 in Patients With Recurrent or Metastatic Head and Neck Cancer Refractory to Platinum Based Chemotherapy
NCT00737360CI-TRIAL-00007943terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TAS-106 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: TAS-106
Primary outcomes (1)
- measure
- Progression Free Survival(PFS)
- timeFrame
- From the date of registration until the earliest date of documented disease progression, death, or censoring event.
- description
- PFS was calculated as days from the date of registration until the earliest date of documented disease progression, death, or censoring event.
Secondary outcomes (3)
- measure
- Antitumor Activity
- timeFrame
- Obtain a contrast-enhanced CT scan of the chest, abdomen and pelvis (if clinically indicated) within 28 days prior to study entry and repeat at the end of every 2 courses thereafter.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 ≤ years old at study entry * Histologically confirmed head and neck carcinoma * Received prior platinum based regimen and developed disease progression or recurrence * Measurable disease according to RECIST guidelines Exclusion Criteria: * Radiological or clinical evidence of brain involvement or leptomeningeal disease * ≥ grade 2 peripheral neuropathy * History of another malignancy
References
Publications (0)
Data not yet available
No reference posted for this study.